Prion meeting 2023: implications of a growing field

Tiago F. Outeiro,Tuane C. R. G. Vieira

DOI: https://doi.org/10.1080/19336896.2024.2343535

2024-04-25

Prion

Abstract:The history of human prion diseases began with the original description, by Hans Gerhard Creutzfeldt and by Alfons Maria Jakob, of patients with a severe brain disease that included speech abnormalities, confusion, and myoclonus, in a disease that was then named Creutzfeldt Jakob disease (CJD). Later, in Papua New Guinea, a disease characterized by trembling was identified, and given the name "Kuru". Neuropathological examination of the brains from CJD and Kuru patients, and of brains of sheep with scrapie disease revealed significant similarities and suggested a possible common mode of infection that, at the time, was thought to derive from an unknown virus that caused slow infections. John Stanley Griffith hypothesized that the agent causing these diseases was "probably a protein without nucleic acid" and, in 1982, Stanley Prusiner reported the identification of a proteinaceous infectious particle (coining the term prion) that was resistant to inactivation methods that were at the time standard for nucleic acids, and identified PrP as the major protein component of the infectious agent in scrapie and in Creutzfeldt-Jakob disease, classifying this also as a prion disease. Interestingly, the prion concept had been previously expanded to yeast proteins capable of replicating their conformation, seeding their own aggregation and transmitting phenotypic information. The prion concept has been more recently expanded to refer to misfolded proteins that are capable of converting a normal form of a protein into an abnormal form. The quest to understand and treat prion diseases has united a specific research community around the topic, and regular meetings (Prion Meetings) have taken place over the years to enable discussions, train junior researchers, and inspire research in the field.

biochemistry & molecular biology

What problem does this paper attempt to address?

The paper mainly discusses the content related to the Prion Meeting 2023, which covers the latest advancements in prion diseases and their related research fields. The main issues the paper attempts to address are as follows:

1. **Review of the history of prion diseases**: The paper first reviews the history of prion diseases, including their early discovery, naming, and subsequent research progress, such as John Stanley Griffith's protein-only hypothesis and Stanley Prusiner's identification of the prion protein (PrP).

2. **Introduction to the expanded concept of prion diseases**: The concept of prions has expanded from the initial prion protein to other proteins capable of self-replication and spreading abnormal conformations, such as those involved in Alzheimer's and Parkinson's diseases.

3. **Overview of the conference organization and content**: A detailed introduction to the organization of the Prion Meeting 2023, the selection of the venue, and its scientific agenda. The conference covered multiple topics, including protein structure and function, yeast prions, mechanisms of pathological transmission, biomarkers, and therapeutic strategies.

4. **Emphasis on the importance of basic research**: Despite significant progress in prion disease research, the paper emphasizes the need to strengthen basic scientific research to promote clinical translational applications and ultimately alleviate human suffering.

5. **Demonstration of the value of interdisciplinary collaboration**: The conference showcased the importance of collaboration between different disciplines in understanding complex biological phenomena and emphasized the connection between basic research and clinical applications.

In summary, this paper aims to summarize the important outcomes of the Prion Meeting 2023 and highlight the fundamental scientific significance of continuing in-depth research on prion diseases and related conditions.